Shots:
- Kling Bio has entered into a collaboration & license option agreement with Sanofi to discover antibodies & epitopes leveraging Kling Bio’s Kling-Select platform
- Collaboration aims to discover & characterize monoclonal antibodies with strong neutralizing activity against human viral pathogen to allow development of novel antiviral therapies
- Kling-Select is a validated B cell immortalization platform that uses pts-derived B cells to discover potent neutralizing antibodies & conserved viral epitopes. Its function-first screening accelerates vaccine development by revealing rare & highly effective immune targets
Ref: PRNewswire | Image: Kling Bio & Sanofi | Press Release
Related News:- NKGen Biotech Partners with HekaBio to Accelerate Troculeucel Development in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
